Fetal hemoglobin gene activation in a Phase II study of 5,6-dihydro-5-azacytidine for bronchogenic carcinoma

B. I. Carr, S. Rahbar, J. H. Doroshow, D. Blayney, D. Goldberg, L. Leong, Y. Asmeron

Research output: Contribution to journalArticle

Abstract

5-Azacytidine and several of its analogues are known to inhibit DNA methylation, alter gene expression, and inhibit cell growth. We report a Phase II study in which we investigated the antineoplastic activity of 5,6-dihydro-5-azacytidine and its induction of fetal hemoglobin synthesis when given by a 5-day continuous i.v. infusion of 1650 mg/m2/day that was repeated every 21 days. Fetal hemoglobin was measured in all patients; increased synthesis was found in 13 of the 17, in the absence of clinically significant anemia. Of the four patients who did not develop increased fetal hemoglobin, three had only one cycle of therapy. Fourteen patients with bronchogenic carcinoma were treated, and ten were evaluable for disease response. Five patients had disease stability of 2 or more mo, and five progressed on treatment. Three additional patients with mesothelioma were treated, and the two who were evaluable for disease response had stabilization of their disease. Fifteen of the 17 patients who received 5,6-dihydro-5-azacytidine developed a pleuritic-type chest pain, 12 had abnormal electrocardiograms, and four developed positive antinuclear antibodies. No significant hemopoietic, hepatic, or renal toxicities were observed. This study demonstrates that 5,6-dihydro-5-azacytidine in the dose and schedule used has no significant therapeutic activity in the treatment of lung cancer but does possess an unusual spectrum of clinical toxicities as well as the property of inducing fetal hemoglobin synthesis.

Original languageEnglish
Pages (from-to)4199-4201
Number of pages3
JournalCancer Research
Volume47
Issue number15
Publication statusPublished - 1987

Fingerprint

5,6-dihydro-5-azacytidine
Fetal Hemoglobin
Bronchogenic Carcinoma
Transcriptional Activation
Azacitidine
Antinuclear Antibodies
Mesothelioma
DNA Methylation
Therapeutics
Chest Pain
Antineoplastic Agents
Anemia
Lung Neoplasms
Appointments and Schedules
Electrocardiography
Kidney
Gene Expression

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Carr, B. I., Rahbar, S., Doroshow, J. H., Blayney, D., Goldberg, D., Leong, L., & Asmeron, Y. (1987). Fetal hemoglobin gene activation in a Phase II study of 5,6-dihydro-5-azacytidine for bronchogenic carcinoma. Cancer Research, 47(15), 4199-4201.

Fetal hemoglobin gene activation in a Phase II study of 5,6-dihydro-5-azacytidine for bronchogenic carcinoma. / Carr, B. I.; Rahbar, S.; Doroshow, J. H.; Blayney, D.; Goldberg, D.; Leong, L.; Asmeron, Y.

In: Cancer Research, Vol. 47, No. 15, 1987, p. 4199-4201.

Research output: Contribution to journalArticle

Carr, BI, Rahbar, S, Doroshow, JH, Blayney, D, Goldberg, D, Leong, L & Asmeron, Y 1987, 'Fetal hemoglobin gene activation in a Phase II study of 5,6-dihydro-5-azacytidine for bronchogenic carcinoma', Cancer Research, vol. 47, no. 15, pp. 4199-4201.
Carr BI, Rahbar S, Doroshow JH, Blayney D, Goldberg D, Leong L et al. Fetal hemoglobin gene activation in a Phase II study of 5,6-dihydro-5-azacytidine for bronchogenic carcinoma. Cancer Research. 1987;47(15):4199-4201.
Carr, B. I. ; Rahbar, S. ; Doroshow, J. H. ; Blayney, D. ; Goldberg, D. ; Leong, L. ; Asmeron, Y. / Fetal hemoglobin gene activation in a Phase II study of 5,6-dihydro-5-azacytidine for bronchogenic carcinoma. In: Cancer Research. 1987 ; Vol. 47, No. 15. pp. 4199-4201.
@article{0388258d6f08405a996e0d867975a5ce,
title = "Fetal hemoglobin gene activation in a Phase II study of 5,6-dihydro-5-azacytidine for bronchogenic carcinoma",
abstract = "5-Azacytidine and several of its analogues are known to inhibit DNA methylation, alter gene expression, and inhibit cell growth. We report a Phase II study in which we investigated the antineoplastic activity of 5,6-dihydro-5-azacytidine and its induction of fetal hemoglobin synthesis when given by a 5-day continuous i.v. infusion of 1650 mg/m2/day that was repeated every 21 days. Fetal hemoglobin was measured in all patients; increased synthesis was found in 13 of the 17, in the absence of clinically significant anemia. Of the four patients who did not develop increased fetal hemoglobin, three had only one cycle of therapy. Fourteen patients with bronchogenic carcinoma were treated, and ten were evaluable for disease response. Five patients had disease stability of 2 or more mo, and five progressed on treatment. Three additional patients with mesothelioma were treated, and the two who were evaluable for disease response had stabilization of their disease. Fifteen of the 17 patients who received 5,6-dihydro-5-azacytidine developed a pleuritic-type chest pain, 12 had abnormal electrocardiograms, and four developed positive antinuclear antibodies. No significant hemopoietic, hepatic, or renal toxicities were observed. This study demonstrates that 5,6-dihydro-5-azacytidine in the dose and schedule used has no significant therapeutic activity in the treatment of lung cancer but does possess an unusual spectrum of clinical toxicities as well as the property of inducing fetal hemoglobin synthesis.",
author = "Carr, {B. I.} and S. Rahbar and Doroshow, {J. H.} and D. Blayney and D. Goldberg and L. Leong and Y. Asmeron",
year = "1987",
language = "English",
volume = "47",
pages = "4199--4201",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "15",

}

TY - JOUR

T1 - Fetal hemoglobin gene activation in a Phase II study of 5,6-dihydro-5-azacytidine for bronchogenic carcinoma

AU - Carr, B. I.

AU - Rahbar, S.

AU - Doroshow, J. H.

AU - Blayney, D.

AU - Goldberg, D.

AU - Leong, L.

AU - Asmeron, Y.

PY - 1987

Y1 - 1987

N2 - 5-Azacytidine and several of its analogues are known to inhibit DNA methylation, alter gene expression, and inhibit cell growth. We report a Phase II study in which we investigated the antineoplastic activity of 5,6-dihydro-5-azacytidine and its induction of fetal hemoglobin synthesis when given by a 5-day continuous i.v. infusion of 1650 mg/m2/day that was repeated every 21 days. Fetal hemoglobin was measured in all patients; increased synthesis was found in 13 of the 17, in the absence of clinically significant anemia. Of the four patients who did not develop increased fetal hemoglobin, three had only one cycle of therapy. Fourteen patients with bronchogenic carcinoma were treated, and ten were evaluable for disease response. Five patients had disease stability of 2 or more mo, and five progressed on treatment. Three additional patients with mesothelioma were treated, and the two who were evaluable for disease response had stabilization of their disease. Fifteen of the 17 patients who received 5,6-dihydro-5-azacytidine developed a pleuritic-type chest pain, 12 had abnormal electrocardiograms, and four developed positive antinuclear antibodies. No significant hemopoietic, hepatic, or renal toxicities were observed. This study demonstrates that 5,6-dihydro-5-azacytidine in the dose and schedule used has no significant therapeutic activity in the treatment of lung cancer but does possess an unusual spectrum of clinical toxicities as well as the property of inducing fetal hemoglobin synthesis.

AB - 5-Azacytidine and several of its analogues are known to inhibit DNA methylation, alter gene expression, and inhibit cell growth. We report a Phase II study in which we investigated the antineoplastic activity of 5,6-dihydro-5-azacytidine and its induction of fetal hemoglobin synthesis when given by a 5-day continuous i.v. infusion of 1650 mg/m2/day that was repeated every 21 days. Fetal hemoglobin was measured in all patients; increased synthesis was found in 13 of the 17, in the absence of clinically significant anemia. Of the four patients who did not develop increased fetal hemoglobin, three had only one cycle of therapy. Fourteen patients with bronchogenic carcinoma were treated, and ten were evaluable for disease response. Five patients had disease stability of 2 or more mo, and five progressed on treatment. Three additional patients with mesothelioma were treated, and the two who were evaluable for disease response had stabilization of their disease. Fifteen of the 17 patients who received 5,6-dihydro-5-azacytidine developed a pleuritic-type chest pain, 12 had abnormal electrocardiograms, and four developed positive antinuclear antibodies. No significant hemopoietic, hepatic, or renal toxicities were observed. This study demonstrates that 5,6-dihydro-5-azacytidine in the dose and schedule used has no significant therapeutic activity in the treatment of lung cancer but does possess an unusual spectrum of clinical toxicities as well as the property of inducing fetal hemoglobin synthesis.

UR - http://www.scopus.com/inward/record.url?scp=0023277806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023277806&partnerID=8YFLogxK

M3 - Article

C2 - 2440559

AN - SCOPUS:0023277806

VL - 47

SP - 4199

EP - 4201

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 15

ER -